Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
- PMID: 27333090
- DOI: 10.1097/MNM.0000000000000566
Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging
Abstract
Purpose: Ga-PSMA-11 is a novel PET tracer suggested to be used for imaging of advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of Ga-PSMA-11, including physiological and benign variants of prostate-specific membrane antigen (PSMA) imaging.
Materials and methods: We carried out a retrospective analysis of 40 patients who underwent PSMA PET/computed tomography (CT) imaging and who had no evidence of residual or metastatic disease on the scans. In addition, 16 patients who underwent PSMA PET/CT imaging with any indication other than prostate cancer were included in the study to evaluate physiological uptake in the normal prostate gland. The median, minimum-maximum, and mean standardized uptake value (SUV) values were calculated for visceral organs, bone marrow and lymph nodes, and mucosal areas. Any physiological variants or benign lesions with Ga-PSMA-11 were also noted.
Results: Ga-PSMA-11 uptake was noted in the kidneys, parotid and submandibular glands, duodenum, small intestines, spleen, liver, and lacrimal glands, and mucosal uptake in the nasopharynx, vocal cords, pancreas, stomach, mediastinal blood pool, thyroid gland, adrenal gland, rectum, vertebral bone marrow, and testes. Celiac ganglia showed slight Ga-PSMA-11 uptake in 24 of 40 patients without the presence of any other pathologic lymph nodes in abdominal and pelvic areas. Variable uptake of Ga-PSMA-11 was observed in calcified choroid plexus, a thyroid nodule, an adrenal nodule, axillary lymph nodes and celiac ganglia, occasional osteophytes, and gallbladder. The patient group with PSMA PET/CT for indications other than prostate cancer (n=16) showed a slight radiotracer uptake in normal prostate gland (SUVmax: 5.5±1.6, range: 3.5-8.3).
Conclusion: This study shows normal distribution pattern, range of SUVs, and physiological variants of Ga-PSMA-11. In addition, several potential pitfalls were documented to prevent misinterpretations of the scan.
Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.Mol Imaging Biol. 2016 Jun;18(3):428-36. doi: 10.1007/s11307-016-0945-x. Mol Imaging Biol. 2016. PMID: 27038316
-
Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity.J Nucl Med. 2021 Aug 1;62(8):1082-1088. doi: 10.2967/jnumed.120.251447. Epub 2020 Dec 4. J Nucl Med. 2021. PMID: 33277394
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
[68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.Expert Rev Mol Diagn. 2024 Jul;24(7):565-582. doi: 10.1080/14737159.2024.2383439. Epub 2024 Jul 25. Expert Rev Mol Diagn. 2024. PMID: 39054633 Review.
Cited by
-
Total-body PET/CT with half-dose [68 Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [68 Ga]Ga-PSMA-11.Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):581-589. doi: 10.1007/s00259-023-06466-z. Epub 2023 Oct 11. Eur J Nucl Med Mol Imaging. 2024. PMID: 37819451
-
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy.Cancers (Basel). 2020 May 26;12(6):1367. doi: 10.3390/cancers12061367. Cancers (Basel). 2020. PMID: 32466595 Free PMC article. Review.
-
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.Nat Rev Urol. 2020 Feb;17(2):107-118. doi: 10.1038/s41585-019-0272-5. Epub 2020 Jan 14. Nat Rev Urol. 2020. PMID: 31937920 Review.
-
68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data.Cancers (Basel). 2022 Jan 11;14(2):334. doi: 10.3390/cancers14020334. Cancers (Basel). 2022. PMID: 35053499 Free PMC article.
-
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.Sci Rep. 2017 Jul 12;7(1):5202. doi: 10.1038/s41598-017-05481-z. Sci Rep. 2017. PMID: 28701709 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous